ongitudinal Efficacy and Safety Study of Tolvaptan on Autosomal Dominant Polycystic Kidney Disease Patients
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- Registration Number
- JPRN-UMIN000021267
- Lead Sponsor
- Autosomal Dominant Polycystic Kidney Disease Research Section, Kyorin University, School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 119
Not provided
1) Patients who have been taking tolvaptan since the TEMPO study 2) Patients who are not eligible, at the discretion of Kyorin University Hospital, to take tolvaptan for the stated indication according to the criteria for careful administration of Samsca as specified by the Ministry of Health, Labour and Welfare - Patients with a history of hypersensitivity to tolvaptan or similar chemical compounds - Patients who do not feel thirsty or have difficulty swallowing water - Patients with hypernatremia - Patients with eGFR less than 15 mL/min/1.73 m2 - Patients with chronic hepatitis, drug-induced hepatic dysfunction or other hepatic dysfunctions - Pregnant women or women suspected of being pregnant. Female patients who wish to become pregnant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method